Barclays’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $201M | Buy |
|
|||||
|
2025
Q2 | $42.9M | Buy |
|
|||||
|
2025
Q1 | $13.4M | Sell |
|
|||||
|
2024
Q4 | $35M | Sell |
|
|||||
|
2024
Q3 | $51.6M | Sell |
|
|||||
|
2024
Q2 | $62M | Buy |
|
|||||
|
2024
Q1 | $40.3M | Sell |
|
|||||
|
2023
Q4 | $60.2M | Sell |
|
|||||
|
2023
Q3 | $78.2M | Sell |
|
|||||
|
2023
Q2 | $104M | Sell |
|
|||||
|
2023
Q1 | $314M | Buy |
|
|||||
|
2022
Q4 | $58.5M | Sell |
|
|||||
|
2022
Q3 | $110M | Buy |
|
|||||
|
2022
Q2 | $70.5M | Sell |
|
|||||
|
2022
Q1 | $131M | Sell |
|
|||||
|
2021
Q4 | $217M | Buy |
|
|||||
|
2021
Q3 | $236M | Sell |
|
|||||
|
2021
Q2 | $259M | Buy |
|
|||||
|
2021
Q1 | $254M | Sell |
|
|||||
|
2020
Q4 | $371M | Sell |
|
|||||
|
2020
Q3 | $500M | Sell |
|
|||||
|
2020
Q2 | $571M | Sell |
|
|||||
|
2020
Q1 | $440M | Buy |
|
|||||
|
2019
Q4 | $355M | Buy |
|
|||||
|
2019
Q3 | $222M | Buy |
|
|||||
|
2019
Q2 | $221M | Buy |
|
|||||
|
2019
Q1 | $211M | Buy |
|
|||||
|
2018
Q4 | $52.4M | Buy |
|
|||||
|
2018
Q3 | $68.8M | Buy |
|
|||||
|
2018
Q2 | $66.4M | Sell |
|
|||||
|
2018
Q1 | $70M | Sell |
|
|||||
|
2017
Q4 | $70.1M | Buy |
|
|||||
|
2017
Q3 | $20M | Sell |
|
|||||
|
2017
Q2 | $36.9M | Sell |
|
|||||
|
2017
Q1 | $38.2M | Sell |
|
|||||
|
2016
Q4 | $36.1M | Sell |
|
|||||
|
2016
Q3 | $85M | Buy |
|
|||||
|
2016
Q2 | $36.2M | Sell |
|
|||||
|
2016
Q1 | $48.4M | Buy |
|
|||||
|
2015
Q4 | $54.1M | Sell |
|
|||||
|
2015
Q3 | $49.8M | Sell |
|
|||||
|
2015
Q2 | $75.8M | Buy |
|
|||||
|
2015
Q1 | $54.7M | Sell |
|
|||||
|
2014
Q4 | $46.5M | Sell |
|
|||||
|
2014
Q3 | $39.3M | Sell |
|
|||||
|
2014
Q2 | $41.1M | Buy |
|
|||||
|
2014
Q1 | $23.8M | Sell |
|
|||||
|
2013
Q4 | $36.4M | Buy |
|
|||||
|
2013
Q3 | $19.4M | Buy |
|
|||||
|
2013
Q2 | $5.23M | Buy |
|